NEW YORK CITY, NY / ACCESS Newswire / June 30, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Evommune, Inc. ("Evommune, Inc.") (NYSE:EVMN) concerning potential violations of the federal securities laws.

Evommune Inc. stock dropped approximately 38% today after the Company disclosed that its Phase 2b trial of EVO756 in moderate-to-severe chronic spontaneous urticaria did not meet its primary endpoint.

EVO756 was Evommune's lead pipeline candidate. The Phase 2b trial measured mean change in UAS7 at 12 weeks in patients with moderate-to-severe CSU -- the trial did not achieve statistical significance on that primary endpoint. Evommune stated it intends to continue developing EVO756 in atopic dermatitis and migraine indications, but the CSU program represented a central component of the Company's near-term clinical strategy.EVO756 was Evommune's lead pipeline candidate. The Phase 2b trial measured mean change in UAS7 at 12 weeks in patients with moderate-to-severe CSU -- the trial did not achieve statistical significance on that primary endpoint. Evommune stated it intends to continue developing EVO756 in atopic dermatitis and migraine indications, but the CSU program represented a central component of the Company's near-term clinical strategy.

The stock decline followed a period in which Evommune's share price had reflected expectations around the CSU data readout. Investors who purchased EVMN shares leading up to the June 29, 2026 disclosure absorbed the full impact of today's single-session drop.

If you suffered a loss on your Evommune, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP



View the original press release on ACCESS Newswire

COMTEX_485198474/2457/2026-06-30T11:52:07